US · Healthcare · Diagnostics & Research
EPS came in at -0.89 against a street estimate of -0.74 — a miss of 20.3%.
Analysts rate Guardant Health Inc a strong buy (25 buy, 0 hold, 1 sell out of 26) with an average price target of $202.24.
CONFIDENT GH delivered $335M revenue (+44% YoY) across oncology, screening, and biopharma. FDA approved Guardant360 Liquid CDx and lower-COGS Shield workflow. UnitedHealth coverage and ACS guidelines unlock 70M lives in screening market. Q2 2026 No geographic breakdown provided. Analysts pressed on UnitedHealth's surprise coverage timing, ADLT pricing uplift mechanics, and timing of Reveal MolDX approvals. Management emphasized surprise nature of UnitedHealth win, guided to ADLT $8,455 pricing yielding ~$5K Guardant360 ASP over 12–24 months, and reiterated hopeful timing for Reveal breast/IO by year-end without guarantees. 2026-07-30…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 5.68% |
| T. Rowe Price Associates, Inc. | 4.85% |
| Vanguard Capital Management, LLC | 4.29% |
| FMR Inc | 4.09% |
| Vanguard Portfolio Management, LLC | 4.06% |
| Amvescap Plc. | 3.30% |
| The Goldman Sachs Group Inc | 2.81% |
| Two Sigma Investments LLC | 2.77% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $360.975 million, up from $265.196 million in the third quarter of 2025. • Nine-month 2026 revenue | 2026-11-05 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $361.0 million, up 36% from $265.2 million in the third quarter of 2025. • GAAP net loss was $124. | 2026-11-05 |
| Board / officer change · Q4 2026 OTHER NOTABLE POINTS • Guardant Health appointed Kevin R. Sayer, 68, to its Board of Directors effective November 2, 2026. The Board now has 11 direc | 2026-11-03 |
| Board / officer change · Q4 2026 OTHER NOTABLE POINTS • Guardant Health granted performance-based restricted stock units (PSUs) to each Co-CEO and founder, Helmy Eltoukhy and AmirAli | 2026-11-03 |
| Quarterly report · Q2 2026 GUARDANT HEALTH, INC. — Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Q2 2026 revenue: $334.98 million (vs. $232.09 million in Q2 2025) — 44% year-over-ye | 2026-07-30 |
| Results announced · Q3 2026 GUARDANT HEALTH Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 revenue: $335.0 million (44% increase year-over-year from $232.1 million in Q2 | 2026-07-30 |
| Shareholder vote results · Q2 2026 GUARDANT HEALTH, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held June 17, 2026 • Total votes cast across proposals: approximat | 2026-06-18 |
| Quarterly report · Q1 2026 GUARDANT HEALTH, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue: $301.7 million (Q1 2026) vs. $203.5 million (Q1 2025) – 48% year-over-year | 2026-05-07 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Guardant Health Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.